• LAST PRICE
    6.2550
  • TODAY'S CHANGE (%)
    Trending Up0.0512 (0.8253%)
  • Bid / Lots
    6.1000/ 11
  • Ask / Lots
    6.5000/ 1
  • Open / Previous Close
    6.1169 / 6.2038
  • Day Range
    Low 6.0101
    High 6.2550
  • 52 Week Range
    Low 4.7515
    High 15.4100
  • Volume
    2,365
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 6.2038
TimeVolumePRPO
09:36 ET1406.1169
09:57 ET7506.016
11:11 ET11576.255
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPRPO
Precipio Inc
8.8M
-0.8x
---
United StatesBTCY
Biotricity Inc
12.6M
-0.8x
---
United StatesNUWE
Nuwellis Inc
2.7M
0.0x
---
United StatesAPYI
Arypsa Inc
30.0
0.0x
---
United StatesAVGR
Avinger Inc
5.0M
-0.1x
---
United StatesRSLS
ReShape Lifesciences Inc
4.3M
0.0x
---
As of 2024-03-28

Company Information

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

Contact Information

Headquarters
12325 Emmet StOMAHA, NE, United States 68164-4243
Phone
203-787-7888
Fax
302-655-5049

Executives

Independent Chairman of the Board
Richard Sandberg
Chief Executive Officer, Founder, Director
Ilan Danieli
Interim Chief Financial Officer
Matthew Gage
Chief Operations Officer
Ahmed Zaki Sabet
Chief Legal Counsel and People Officer
Miri Chiko-radomski

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$8.8M
Revenue (TTM)
$13.3M
Shares Outstanding
1.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.62
EPS
$-7.54
Book Value
$14.29
P/E Ratio
-0.8x
Price/Sales (TTM)
0.7
Price/Cash Flow (TTM)
---
Operating Margin
-68.41%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.